Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
Sara Tolaney, MD, MPH, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; and senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses key takeaways from the TROPiCS-02 (NCT03901339) study of sacituzumab govitecan-hziy (Trodelvy) for patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.
According to Tolaney, sacituzumab is an effective and safe treatment option for this patient population, thus FDA approval was granted based on findings from the phase 3 study.
Now, experts are further evaluating sacituzumab and trying to move treatment up in earlier settings.
Transcription:
0:10 | I think now seeing with longer follow-up that there continues to be improvement in both progression-free and overall survival, favoring sacituzumab over standard chemotherapy, it reinforces that fact that sacituzumab is a very effective treatment option for patients with pretreated metastatic hormone receptor-positive disease.
0:26 | There's definitely an interest in trying to move sacituzumab up even earlier. Obviously, this was a very pretreated setting with a median of 3 lines of chemotherapy in the metastatic setting and we all would wonder how sacituzumab would do if given earlier. There is a trial called ASCENT-07 [NCT05840211] which is looking at sacituzumab compared with chemotherapy in the first-line of chemotherapy for metastatic hormone receptor-positive disease.
0:52 | There are also ongoing trials looking at sacituzumab in the first-line, metastatic triple negative breast cancer space, so ASCENT-03 [NCT05382299] and ASCENT-04 [NCT05382286], looking at it in the PD-L1-negative population as well as in the PD-L1-positive population. Then, there's even a trial looking at sacituzumab in early breast cancer. That trial is ASCENT-05 [NCT05633654], looking at patients who had preoperative therapy for triple negative breast cancer and have residual disease. Then, they get randomized to get sacituzumab with pembrolizumab [Keytruda] or to get pembrolizumab plus capcitabine per physicians choice.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More